ACLARIS THERAPEUTICS

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

30 июн 2025 06:31:48 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

26 июн 2025 13:01:27 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

23 июн 2025 03:59:36 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

02 июн 2025 03:59:53 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

28 май 2025 06:20:15 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

09 май 2025 04:00:19 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 май 2025 03:50:51 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

29 апр 2025 04:00:32 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

22 апр 2025 03:59:08 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 мар 2025 04:00:05 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 фев 2025 03:59:55 Источник Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 фев 2025 03:50:01 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 янв 2025 13:01:21 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 янв 2025 13:30:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 дек 2024 13:30:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 ноя 2024 13:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 ноя 2024 06:45:01 Источник NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

18 ноя 2024 06:52:02 Источник NetDania Notify

Aclaris Therapeutics Announces $80 Million Private Placement

18 ноя 2024 05:10:41 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 ноя 2024 05:10:04 Источник Nasdaq GlobeNewswire